A randomized-controlled, double-blinded, phase III study of CS-866AZ

Authors
Category Primary study
JournalJapan Primary Registry Network
Year 2006
INTERVENTION: Intervention name : CS‐866AZ (olmesartan medoxomil / azelnidipine) INN of the intervention : olmesartan medoxomil/azelnidipine Dosage And administration of the intervention : Oral CONDITION: Essential hypertension PRIMARY OUTCOME: Efficacy and safety INCLUSION CRITERIA: Mild to moderate essential hypertension with aged 20 years or older
Epistemonikos ID: f490030cc5dc3ea4e8b98418a50a8c722ee0d846
First added on: Aug 21, 2024